{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:44:42Z","timestamp":1778780682743,"version":"3.51.4"},"reference-count":51,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T00:00:00Z","timestamp":1545868800000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>Patients with Parkinson\u2019s disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP. How best to implement a switch to pimavanserin has not been clear, as there are no controlled trials or case series in the literature to provide guidance. An abrupt switch may interrupt partially effective treatment or potentially trigger rebound effects from antipsychotic withdrawal, whereas cross-taper involves potential drug interactions. A panel of experts drew from published data, their experience treating PDP, lessons from switching antipsychotic drugs in other populations, and the pharmacology of the relevant drugs, to establish consensus recommendations. The panel concluded that patients with PDP can be safely and effectively switched from atypical antipsychotics used off label in PDP to the recently approved pimavanserin by considering each agent\u2019s pharmacokinetics and pharmacodynamics, receptor interactions, and the clinical reason for switching (efficacy or adverse events). Final recommendations are that such a switch should aim to maintain adequate 5-HT<jats:sub>2A<\/jats:sub> antagonism during the switch, thus providing a stable transition so that efficacy is maintained. Specifically, the consensus recommendation is to add pimavanserin at the full recommended daily dose (34 mg) for 2\u20136 weeks in most patients before beginning to taper and discontinue quetiapine or clozapine over several days to weeks. Further details are provided for this recommendation, as well as for special clinical circumstances where switching may need to proceed more rapidly.<\/jats:p>","DOI":"10.1017\/s1092852918001359","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T06:23:07Z","timestamp":1545891787000},"page":"402-413","source":"Crossref","is-referenced-by-count":12,"title":["Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson\u2019s disease psychosis: an expert consensus"],"prefix":"10.1017","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-9567","authenticated-orcid":false,"given":"Kevin J.","family":"Black","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-1094","authenticated-orcid":false,"given":"Henry","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Stacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles H.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Alva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kremens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Menza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin A.","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Simuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbi A.","family":"Morrissette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"S1092852918001359_ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(10)71701-6"},{"key":"S1092852918001359_ref50","unstructured":"Mills R , Isaacson S , Azulay J-P , et al. Long-term effectiveness of NUPLAZID\u00ae (pimavanserin) in PD psychosis: data from 2 open-label studies. Paper presented at: XXI World Congress on Parkinson\u2019s Disease and Related Disorders; December 6\u20139, 2015; Milan, Italy."},{"key":"S1092852918001359_ref48","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852917000736"},{"key":"S1092852918001359_ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-014-1293-3"},{"key":"S1092852918001359_ref45","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017703992"},{"key":"S1092852918001359_ref44","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27378"},{"key":"S1092852918001359_ref42","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21116"},{"key":"S1092852918001359_ref39","doi-asserted-by":"publisher","DOI":"10.3109\/00207450903222758"},{"key":"S1092852918001359_ref38","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000228176.98582.93"},{"key":"S1092852918001359_ref35","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000136891.17006.ec"},{"key":"S1092852918001359_ref34","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.029868"},{"key":"S1092852918001359_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)00860-0"},{"key":"S1092852918001359_ref29","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200401000-00003"},{"key":"S1092852918001359_ref27","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.2-150.v1"},{"key":"S1092852918001359_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92511-9"},{"key":"S1092852918001359_ref22","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23884"},{"key":"S1092852918001359_ref30","doi-asserted-by":"publisher","DOI":"10.1002\/hup.578"},{"key":"S1092852918001359_ref21","doi-asserted-by":"publisher","DOI":"10.2174\/1568026616666160608084834"},{"key":"S1092852918001359_ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0079-5"},{"key":"S1092852918001359_ref17","unstructured":"Mills R , Friedman J , Ondo W , et al. Efficacy and tolerability of NUPLAZID\u00ae (pimavanserin) in PD psychosis: analysis of an integrated phase 3 placebo-controlled dataset. Paper presented at: XXI World Congress on Parkinson\u2019s Disease and Related Disorders; December 6\u20139, 2015; Milan, Italy."},{"key":"S1092852918001359_ref15","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.176"},{"key":"S1092852918001359_ref14","first-page":"268","article-title":"5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics","volume":"299","author":"Weiner","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852918001359_ref13","unstructured":"ACADIA Pharmaceuticals Inc. NUPLAZID\u00ae [package insert]. San Diego, CA; 2016."},{"key":"S1092852918001359_ref12","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.066688"},{"key":"S1092852918001359_ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/656370"},{"key":"S1092852918001359_ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.139"},{"key":"S1092852918001359_ref4","first-page":"184","volume-title":"Non-Motor Symptoms of Parkinson\u2019s Disease","author":"Goetz","year":"2014"},{"key":"S1092852918001359_ref9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781615371624.as24"},{"key":"S1092852918001359_ref41","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20474"},{"key":"S1092852918001359_ref19","first-page":"862","article-title":"Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis","volume":"43","author":"Takeuchi","year":"2017","journal-title":"Schizophr Bull."},{"key":"S1092852918001359_ref7","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000602"},{"key":"S1092852918001359_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2006.07.003"},{"key":"S1092852918001359_ref11","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000342"},{"key":"S1092852918001359_ref37","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000236769.31279.19"},{"key":"S1092852918001359_ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/645429"},{"key":"S1092852918001359_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"S1092852918001359_ref40","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000260060.60870.89"},{"key":"S1092852918001359_ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303"},{"key":"S1092852918001359_ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0031"},{"key":"S1092852918001359_ref24","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000215428.46057.3d"},{"key":"S1092852918001359_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13702"},{"key":"S1092852918001359_ref2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21382"},{"key":"S1092852918001359_ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401003"},{"key":"S1092852918001359_ref43","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S5335"},{"key":"S1092852918001359_ref49","unstructured":"Mathis MV . NDA Approval\/Supplement Approval. In: Center for Drug Evaluation and Research, ed. Silver Spring, MD: Food and Drug Administration; 2018. http:\/\/www.webcitation.org\/query?url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fappletter%2F2018%2F210793Orig1s000%2C207318Orig1s003ltr.pdf&date=2018-07-20"},{"key":"S1092852918001359_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000219"},{"key":"S1092852918001359_ref10","first-page":"266","article-title":"Treatment of Parkinson\u2019s disease psychosis","volume":"27","author":"Black","year":"2017","journal-title":"Med Int Rev"},{"key":"S1092852918001359_ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200510000-00003"},{"key":"S1092852918001359_ref26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1176\/jnp.9.4.594","article-title":"The use of risperidone for psychosis and agitation in demented patients with Parkinson\u2019s disease","volume":"9","author":"Workman","year":"1997","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"S1092852918001359_ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.10.022"},{"key":"S1092852918001359_ref28","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10217"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852918001359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T09:57:45Z","timestamp":1560506265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852918001359\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1092852918001359"],"URL":"https:\/\/doi.org\/10.1017\/s1092852918001359","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}